Printer Friendly

ADVANCED TISSUE SCIENCES AND MITSUBISHI KASEI ENTER AGREEMENT TO EVALUATE DERMAGRAFT(TM) FOR WOUND HEALING IN JAPAN

 LA JOLLA, Calif., Jan 28 /PRNewswire/ -- Advanced Tissue Sciences Inc. (NASDAQ-NMS: ATIS) today announced that it has signed an agreement with Mitsubishi Kasei Corp. to evaluate Dermagraft(TM), Advanced Tissue Sciences' living skin replacement, for its potential use in Japan for the treatment of patients suffering from severe burns and chronic skin ulcers. Terms were not disclosed.
 "We are pleased that Mitsubishi Kasei has expressed a strong interest in exploring the potential of bringing Dermagraft to the Japanese market," said Gail K. Naughton, Ph.D., Advanced Tissue Sciences' executive vice president and chief operating officer. "Mitsubishi's experience with the Japanese regulatory environment and their development and marketing expertise could play an important role in making Dermagraft available to patients in Japan."
 Advanced Tissue Sciences developed Dermagraft using its proprietary tissue engineering technology. Dermagraft is a living human dermal replacement that is currently being used in clinical trials in the United States under an Investigational Device Exemption approved by the U.S. Food and Drug Administration (FDA). Ongoing clinical trials are being conducted to evaluate Dermagraft for the treatment of severe burns and chronic venous skin ulcers. The FDA has granted the company approval to move Dermagraft into clinical trials to treat decubitus and diabetic ulcers as well. Those trials are planned to begin in 1993.
 Mitsubishi Kasei Corp. is a diversified global chemical company with expertise in developing and marketing biopharmaceutical products. Mitsubishi Kasei's biopharmaceutical product line includes GRTPA(R) to treat coronary thrombosis, and the Mitsubishi(R) Hepatitis B vaccine.
 Advanced Tissue Sciences is a tissue engineering company engaged in the growth of human tissues and organs for potential therapeutic and laboratory applications. Using its proprietary three-dimensional culture system, the company has successfully replicated a variety of human tissues including skin, cartilage, oral mucosa, bone marrow and liver.
 -0- 1/28/93
 /CONTACT: Janet Wahl, director of corporate communications of Advanced Tissue Sciences, 619-450-5737/
 (ATIS)


CO: Advanced Tissue Sciences Inc.; Mitsubishi Kasei Corp. ST: California IN: MTC SU:

JL-LS -- SD003 -- 0049 01/28/93 08:32 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 28, 1993
Words:338
Previous Article:LUKENS BOARD OF DIRECTORS APPROVES $86 MILLION CAPITAL EXPANSION AS COMPANY ENTERS NEXT PHASE OF 'LUKENS 2000' STRATEGY FOR GROWTH
Next Article:FRITZ LAUNCHES JOINT VENTURE IN KAZAKHSTAN
Topics:


Related Articles
ADVANCED TISSUE SCIENCES FILES IDE FOR ADDITIONAL BURN PRODUCT
ADVANCED TISSUE SCIENCES REPORTS STATUS OF SKIN ULCER TRIALS AND EXPANSION OF TRIALS TO FRANCE
ADVANCED TISSUE SCIENCES PRESENTS DIABETIC ULCER DATA AT MAJOR SCIENTIFIC MEETINGS
ADVANCED TISSUE SCIENCES RECEIVES APPROVAL TO BEGIN PIVOTAL CLINICAL TRIAL OF DERMAGRAFT(TM) FOR DIABETIC ULCERS
ADVANCED TISSUE SCIENCES REPORTS CHRONIC SKIN ULCER UPDATE
FLUOR DANIEL AWARDED CONTRACT BY ADVANCED TISSUES SCIENCES
Dermagraft(R) Shows Statistical Significance in The Treatment of Diabetic Foot Ulcers; PMA To Be Submitted in December
Advanced Tissue Sciences Announces Submission of Premarket Approval Application for Dermagraft(R) in Diabetic Foot Ulcers
Advanced Tissue Sciences Announces Submission of Premarket Approval Application for Dermagraft(R) in Diabetic Foot Ulcers
Advanced Tissue Sciences and Smith & Nephew Present Dermagraft(R) Pivotal Trial Data At Symposium for Advanced Wound Care;

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters